Goldman Sachs Group Inc. reaffirmed their conviction-buy rating on shares of Shire PLC (LON:SHP) in a research report released on Thursday. They currently have a GBX 6,300 ($82.23) target price on the biopharmaceutical company’s stock.
SHP has been the subject of a number of other reports. JPMorgan Chase & Co. restated an overweight rating and issued a GBX 6,300 ($82.23) target price on shares of Shire PLC in a research note on Tuesday, August 16th. BNP Paribas reiterated an outperform rating and set a GBX 5,700 ($74.40) price objective on shares of Shire PLC in a research note on Wednesday, June 15th. Deutsche Bank AG reiterated a buy rating and set a GBX 5,600 ($73.10) price objective on shares of Shire PLC in a research note on Monday, June 13th. Morgan Stanley reiterated an overweight rating and set a GBX 5,600 ($73.10) price objective on shares of Shire PLC in a research note on Friday, June 3rd. Finally, Jefferies Group increased their price objective on Shire PLC from GBX 6,050 ($78.97) to GBX 6,600 ($86.15) and gave the stock a buy rating in a research note on Wednesday, August 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of Buy and an average target price of GBX 5,828 ($76.07).
Shire PLC (LON:SHP) opened at 5111.00 on Thursday. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00. The firm’s market cap is GBX 34.90 billion. The firm has a 50-day moving average of GBX 4,981.91 and a 200-day moving average of GBX 4,529.37.
The firm also recently declared a dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 8th will be given a dividend of GBX 3.51 ($0.05) per share. This represents a dividend yield of 0.07%. The ex-dividend date is Thursday, September 8th.
In other Shire PLC news, insider Dominic Blakemore purchased 133 shares of the company’s stock in a transaction dated Friday, September 30th. The shares were bought at an average price of GBX 5,010 ($65.40) per share, with a total value of £6,663.30 ($8,697.69).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.